Displaying drugs 14351 - 14375 of 14475 in total
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Description: … graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcerative colitis,[L40614] alopecia areata,[L40624] and …
Nifurpirinol
Experimental
Vet approved
Ondelopran
Ondelopran has been used in trials studying the treatment of Alcohol Dependence.
Investigational
CG0070
CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated...
Investigational
Matched Description: … can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and …
Acylated ceftazidime
Experimental
Bilh 434
Experimental
PLX-4720
Experimental
L-778123
Experimental
(S,R)-fidarestat
Experimental
Ceftazidime BATSI
Experimental
Febantel
Experimental
Vet approved
L-naphthyl-1-acetamido boronic acid alanine
Experimental
{[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid
This compound belongs to the nitrofurans. These are compounds containing a furan ring which bears a nitro group. It targets the protein aldose reductase.
Experimental
Displaying drugs 14351 - 14375 of 14475 in total